Literature DB >> 21117080

A new regulatory switch in a JAK protein kinase.

Vickie Tsui1, Paul Gibbons, Mark Ultsch, Kyle Mortara, Christine Chang, Wade Blair, Rebecca Pulk, Mark Stanley, Melissa Starovasnik, David Williams, Maria Lamers, Phillip Leonard, Steven Magnuson, Jun Liang, Charles Eigenbrot.   

Abstract

Members of the JAK family of protein kinases mediate signal transduction from cytokine receptors to transcription factor activation. Over-stimulation of these pathways is causative in immune disorders like rheumatoid arthritis, psoriasis, lupus, and Crohn's disease. A search for selective inhibitors of a JAK kinase has led to our characterization of a previously unknown kinase conformation arising from presentation of Tyr962 of TYK2 to an inhibitory small molecule via an H-bonding interaction. A small minority of protein kinase domains has a Tyrosine residue in this position within the αC-β4 loop, and it is the only amino acid commonly seen here with H-bonding potential. These discoveries will aid design of inhibitors that discriminate among the JAK family and more widely among protein kinases.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21117080     DOI: 10.1002/prot.22889

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  9 in total

1.  Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Authors:  Patrick J Lupardus; Mark Ultsch; Heidi Wallweber; Pawan Bir Kohli; Adam R Johnson; Charles Eigenbrot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

2.  Targeted kinase selectivity from kinase profiling data.

Authors:  Francesca Milletti; Johannes C Hermann
Journal:  ACS Med Chem Lett       Date:  2012-03-14       Impact factor: 4.345

3.  Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.

Authors:  Sangkil Nam; Wei Wen; Anne Schroeder; Andreas Herrmann; Hua Yu; Xinlai Cheng; Karl-Heinz Merz; Gerhard Eisenbrand; Hongzhi Li; Yate-Ching Yuan; Richard Jove
Journal:  Mol Oncol       Date:  2012-11-16       Impact factor: 6.603

4.  A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.

Authors:  Sue J Sohn; Kathy Barrett; Anne Van Abbema; Christine Chang; Pawan Bir Kohli; Hidenobu Kanda; Janice Smith; Yingjie Lai; Aihe Zhou; Birong Zhang; Wenqian Yang; Karen Williams; Calum Macleod; Christopher A Hurley; Janusz J Kulagowski; Nicholas Lewin-Koh; Hart S Dengler; Adam R Johnson; Nico Ghilardi; Mark Zak; Jun Liang; Wade S Blair; Steven Magnuson; Lawren C Wu
Journal:  J Immunol       Date:  2013-07-26       Impact factor: 5.422

5.  Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.

Authors:  Calliope A Dendrou; Adrian Cortes; Lydia Shipman; Hayley G Evans; Kathrine E Attfield; Luke Jostins; Thomas Barber; Gurman Kaur; Subita Balaram Kuttikkatte; Oliver A Leach; Christiane Desel; Soren L Faergeman; Jane Cheeseman; Matt J Neville; Stephen Sawcer; Alastair Compston; Adam R Johnson; Christine Everett; John I Bell; Fredrik Karpe; Mark Ultsch; Charles Eigenbrot; Gil McVean; Lars Fugger
Journal:  Sci Transl Med       Date:  2016-11-02       Impact factor: 17.956

6.  TYK2 kinase activity is required for functional type I interferon responses in vivo.

Authors:  Michaela Prchal-Murphy; Christian Semper; Caroline Lassnig; Barbara Wallner; Christian Gausterer; Ingeborg Teppner-Klymiuk; Julianna Kobolak; Simone Müller; Thomas Kolbe; Marina Karaghiosoff; Andras Dinnyés; Thomas Rülicke; Nicole R Leitner; Birgit Strobl; Mathias Müller
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

7.  Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant.

Authors:  Stéphanie Boisson-Dupuis; Noe Ramirez-Alejo; Zhi Li; Etienne Patin; Geetha Rao; Gaspard Kerner; Che Kang Lim; Dimitry N Krementsov; Nicholas Hernandez; Cindy S Ma; Qian Zhang; Janet Markle; Ruben Martinez-Barricarte; Kathryn Payne; Robert Fisch; Caroline Deswarte; Joshua Halpern; Matthieu Bouaziz; Jeanette Mulwa; Durga Sivanesan; Tomi Lazarov; Rodrigo Naves; Patricia Garcia; Yuval Itan; Bertrand Boisson; Alix Checchi; Fabienne Jabot-Hanin; Aurélie Cobat; Andrea Guennoun; Carolyn C Jackson; Sevgi Pekcan; Zafer Caliskaner; Jaime Inostroza; Beatriz Tavares Costa-Carvalho; Jose Antonio Tavares de Albuquerque; Humberto Garcia-Ortiz; Lorena Orozco; Tayfun Ozcelik; Ahmed Abid; Ismail Abderahmani Rhorfi; Hicham Souhi; Hicham Naji Amrani; Adil Zegmout; Frédéric Geissmann; Stephen W Michnick; Ingrid Muller-Fleckenstein; Bernhard Fleckenstein; Anne Puel; Michael J Ciancanelli; Nico Marr; Hassan Abolhassani; María Elvira Balcells; Antonio Condino-Neto; Alexis Strickler; Katia Abarca; Cory Teuscher; Hans D Ochs; Ismail Reisli; Esra H Sayar; Jamila El-Baghdadi; Jacinta Bustamante; Lennart Hammarström; Stuart G Tangye; Sandra Pellegrini; Lluis Quintana-Murci; Laurent Abel; Jean-Laurent Casanova
Journal:  Sci Immunol       Date:  2018-12-21

8.  Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy.

Authors:  Venky Soundararajan; Murali Aravamudan
Journal:  Sci Rep       Date:  2014-12-03       Impact factor: 4.379

9.  Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis.

Authors:  Leonie C S De Vries; Mohammed Ghiboub; Patricia H P van Hamersveld; Olaf Welting; Caroline Verseijden; Matthew J Bell; Inmaculada Rioja; Rabinder K Prinjha; Pim J Koelink; Birgit Strobl; Mathias Müller; Geert R D'Haens; Manon E Wildenberg; Wouter J De Jonge
Journal:  J Crohns Colitis       Date:  2021-04-06       Impact factor: 9.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.